Gastrointestinal disorders in children with neurodevelopmental disabilities. od Sullivan, P

Demography of aging and the epidemiology of gastrointestinal disorders in the elderly od Goldacre, M

“...Many of the gastrointestinal disorders seen in specialist practise show age-specific incidence and prevalence rates that increase substantially with increasing age. ...”

Demography of aging and the epidemiology of gastrointestinal disorders in the elderly. od Goldacre, M

“...Many of the gastrointestinal disorders seen in specialist practise show age-specific incidence and prevalence rates that increase substantially with increasing age. ...”

Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. od Sanger, G, Chang, L, Bountra, C, Houghton, L

“...Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. ...”

Immune modulation in gastrointestinal disorders: new opportunities for therapeutic peptides? od de Jonge, W, Greaves, D

Characterization of Bacillus species used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders. od Hoa, N, Baccigalupi, L, Huxham, A, Smertenko, A, Van, P, Ammendola, S, Ricca, E, Cutting, A

“...Bacillus subtilis spores are being used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders in both humans and animals. Since B. subtilis is an aerobic saprophyte, how spores may benefit the gut microbiota is an intriguing question, since other probiotics such as Lactobacillus spp. which colonize the gut are anerobes. ...”

Gastrointestinal disorders in Curry-Jones syndrome: clinical and molecular insights from an affected newborn od Wigby, K, Twigg, S, Broderick, R, Davenport, K, Wilkie, A, Bickler, S, Jones, M

Cognitive processing in putative functional gastrointestinal disorder: rumination yields orientation to social threat not pain. od Martin, M, Chapman, S

“...Two possible roles of selective attention in the development and maintenance of functional gastrointestinal disorders (FGID) such as irritable bowel syndrome (IBS) were examined. ...”

Epidemiology of H. pylori and its relation with gastrointestinal disorders, a community-based study in Dhaka, Bangladesh od Nahar, S, Kibria, KM, Hossain, Md. E, Sarker, SA, Bardhan, PK, Talukder, KA, Rahman, M

Higher prevalence and severity of both anxiety and depression in functional gastrointestinal disorders than controls: Irritable Bowel Syndrome (IBS) more than Functional Dyspepsia (FD) and Non Erosive Reflux Disease (NERD)? od Leo, H.J., Sanjiv, M., Lee, G.K.

Mode of action for gastroprotective activity of Muntingia calabura L. leaves in rats od Balan, Tavamani

“...Gastric ulcer is one of the most common gastrointestinal disorders. As current antiulcer treatments are associated with wide range of side effects, there is a need to discover an effective and safer new antiulcer agent. ...”
Polni tekst

Four exons of the serotonin receptor 4 gene are associated with multiple distant branch points. od Hallegger, M, Sobala, A, Smith, C

“...The human HTR4 gene, which encodes serotonin receptor 4 and has been associated with schizophrenia, bipolar disease, and gastrointestinal disorders, has four exons with extensive AGEZs. ...”

Diversity and utilization of ethnomedicinal plants in Sarawak, Borneo od Abu Bakar, Fauziah, Khan, Waseem Razzaq, Khan, Ishfaq Ahmad, Magiman, Mohamad Maulana, Rosli, Zamri, Seemab, Akram, I., Faridah-Hanum

“...A total of 166 therapeutic plants were utilized by native communities of Sarawak, where most of the plant species were used to treat gastrointestinal disorders and cardiovascular illnesses. Most plant species used for medicinal purposes belong to Rubiaceae, Piperaceae, Leguminosae, Lamiaceae, Annonaceae, and Zingiberaceae. ...”

Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits od Pasupuleti, Visweswara Rao, Sammugam, Lakhsmi, Ramesh, Nagesvari, Siew, Hua Gan

“...Propolis has been reported to have various health benefits related to gastrointestinal disorders, allergies, and gynecological, oral, and dermatological problems. ...”
Polni tekst

Ingestible Electronics for High Quality Gastric Neural Recordings od Gierlach, Adam Matthew

“...Recent advances in understanding the gut-brain axis, functional gastrointestinal disorders, and gastric stimulation therapies have highlighted the importance of the electrical signals that regulate the gastrointestinal (GI) tract. ...”
Polni tekst

Physiological effects of dietary complex carbohydrates and its metabolites role in certain diseases od Khattak, Muhammad Muzaffar Ali Khan

“...These diseases are obesity, coronary heart disease, colonic cancer and gastrointestinal disorders (diverticular disease, constipation, hiatal hernia and hemorrhoids). ...”
Polni tekst

Anti-ulcerogenic activity of gynura procumbens leaf extract against experimentally-induced gastric lesions in rats od Mahmood, A.A., Mariod, A.A., Al-Bayaty, F., Abdel-Wahab, S.I.

“...Several plants are used in folk medicine to treat gastrointestinal disorders. Gynura procumbens is a medicinal plant commonly used in traditional treatment of many aliments. ...”

Revolutionizing ghee production through Moringa Oleifera SP. flavor infusion (ID110) od Asogan, Arjun, Norazlianie, Sazali

“...The resulting product not only showcases improved aroma and texture but also addresses health concerns such as mobility issues, gastrointestinal disorders, and excessive weight. With 75 kg already sold directly, this fusion of gastronomy and wellness resonates with a discerning market. ...”
Polni tekst
Polni tekst

MYBIOTA: a birth cohort on maternal and infant microbiota and its impact on infant health in Malaysia od Eow, Shiang Yen, Gan, Wan Ying, Jiang, Tiemin, Loh, Su Peng, Lee, Ling Jun, Chin, Yit Siew, Thian, Leslie Lung Than, How, Kang Nien, Thong, Pui Ling, Liu, Yanpin, Zhao, Junying, Chen, Lijun

“...Objective: The MYBIOTA is a prospective mother-infant cohort study in Malaysia aiming to determine the association between gut microbiota with infant health (temperament, gastrointestinal disorders, eczema, asthma, and developmental delays) in Selangor, Malaysia. ...”

Adverse events in people taking macrolide antibiotics versus placebo for any indication od Hansen, M, Scott, A, McCullough, A, Thorning, S, Aronson, J, Beller, E, Glasziou, P, Hoffmann, T, Clark, J, Mar, D

“...Vomiting (OR 1.27, 95% CI 1.04 to 1.56; moderate-quality evidence) and gastrointestinal disorders not otherwise specified (NOS) (OR 2.16, 95% CI 1.56 to 3.00; moderate-quality evidence) were also reported more often in participants taking macrolides compared to placebo.The number of additional people (absolute difference in risk) who experienced adverse events from macrolides was: gastrointestinal disorders NOS 85/1000; diarrhoea 72/1000; abdominal pain 62/1000; nausea 47/1000; and vomiting 23/1000.The number needed to treat for an additional harmful outcome (NNTH) ranged from 12 (95% CI 8 to 23) for gastrointestinal disorders NOS to 17 (9 to 47) for abdominal pain; 19 (12 to 33) for diarrhoea; 19 (13 to 30) for nausea; and 45 (22 to 295) for vomiting.There was no clear consistent difference in gastrointestinal adverse events between different types of macrolides or route of administration.Taste disturbances were reported more often by participants taking macrolide antibiotics, although there were wide confidence intervals and moderate heterogeneity (OR 4.95, 95% CI 1.64 to 14.93; I² = 46%; low-quality evidence).Compared with participants taking placebo, those taking macrolides experienced hearing loss more often, however only four studies reported this outcome (OR 1.30, 95% CI 1.00 to 1.70; I² = 0%; low-quality evidence).We did not find any evidence that macrolides caused more cardiac disorders (OR 0.87, 95% CI 0.54 to 1.40; very low-quality evidence); hepatobiliary disorders (OR 1.04, 95% CI 0.27 to 4.09; very low-quality evidence); or changes in liver enzymes (OR 1.56, 95% CI 0.73 to 3.37; very low-quality evidence) compared to placebo.We did not find any evidence that appetite loss, dizziness, headache, respiratory symptoms, blood infections, skin and soft tissue infections, itching, or rashes were reported more often by participants treated with macrolides compared to placebo.Macrolides caused less cough (OR 0.57, 95% CI 0.40 to 0.80; moderate-quality evidence) and fewer respiratory tract infections (OR 0.70, 95% CI 0.62 to 0.80; moderate-quality evidence) compared to placebo, probably because these are not adverse events, but rather characteristics of the indications for the antibiotics. ...”